As for miR-494, previous studies show that estrogen treatment results in the upregulation of miR-494 expression in the human mammary adenocarcinoma cell MCF-7 (27) and the human hepatocarcinoma cell line HuH-7 (28), thus indicating a possible role of miR-494 in the estrogen-mediated downregulation of tissue factor pathway inhibitor α and protein S, respectively. This evidence concerns the gene TFPI and breast adenocarcinoma.